FrancophonIA/ELRC3.0 huggingface dataset:
English: The geometric mean ratio (ratio of pharmacokinetic parameters in hepatically impaired patients to patients with normal liver function) (90% confidence interval) was 0.7 (0.3 to 1.6) for both AUC0-12 and Cmax, which suggests approximately 30% reduction in the pharmacokinetic exposure in patients with moderate hepatic impairment.
Maltese: Il-proporzjon tal-medja ġeometrika (proporzjon ta' parametri farmakokinetiċi f'pazjenti b'indeboliment tal-fwied ma' pazjenti b'funzjoni tal-fwied normali) (intervall ta' konfidenza ta' 90%) kien ta' 0.7 (0.3 sa 1.6) kemm għall-AUC0-12 kif ukoll għal Cmax, li tissuġġerixxi tnaqqis ta' madwar 30% fl-esponiment farmakokinetiku f'pazjenti b'indeboliment moderat tal-fwied.
English: In treatment-naïve HIV-1 infected patients initiating Invirase/ritonavir treatment with a modified Invirase/ritonavir dosing regimen of Invirase 500 mg two times daily with ritonavir 100 mg two times daily for the first 7 days of treatment and increased to Invirase 1000 mg two times daily with ritonavir 100 mg two times daily in the subsequent 7 days, saquinavir systemic exposures generally approached or exceeded the range of historical steady-state values with the standard Invirase/ritonavir 1000 mg/100 mg bid dosing regimen across study days (see Tables 9 and 8).
Maltese: F'pazjent infettati b'HIV-1 li qatt ma ħadu kura qabel, li bdew kura b'Invirase/ritonavir b'kors ta' dożaġġ modifikat ta' Invirase/ritonavir ta' Invirase 500 mg darbtejn kuljum b'ritonavir 100 mg darbtejn kuljum għall-ewwel 7 ijiem ta' kura u żiedu għal Invirase 1000 mg darbtejn kuljum b'ritonavir 100 mg darbtejn kuljum fis-7 ijiem ta' wara, l-esponiment sistemiku għal saquinavir b'mod ġenerali avviċina jew qabeż il-firxa ta' valuri storiċi fi stat fiss bil-kors ta' dożaġġ standard ta' Invirase/ritonavir 1000 mg/100 mg bid tul il-jiem tal-istudju (ara Tabelli 9 u 8).
English: Endothelin receptor antagonist Bosentan
Maltese: Antagonist tar-riċettur tal-endotilju
English: Systemic clearance of saquinavir was high, 1.14 l/h/kg (CV 12 %), slightly above the hepatic plasma flow, and constant after intravenous doses of 6, 36 and 72 mg.
Maltese: It-tneħħija sistematika ta' saquinavir kienet għolja, 1.14 l/h/kg (CV ta' 12 %), ftit aktar miċċirkolazzjoni tal-plażma fil-fwied, u kostanti wara l-għotja ta' dożi ġol-vini ta' 6, 36 u 72 mg.
English: Table 3: Maximum mean of ddQTcS† (msec) on day 3 for therapeutic dose of Invirase/ritonavir, supra-therapeutic dose of Invirase/ritonavir and active control moxifloxacin in healthy volunteers in Thorough QT (TQT) Study
Maltese: (msec) f'ġurnata 3 għad-doża terapewtika ta' Invirase/ritonavir, doża sopra terapewtika ta' Invirase/ritonavir u l-kontroll attiv moxifloxacin f'voluntiera f'saħħithom fl-Istudju bir-reqqa dwar QT (TQT - Thorough QT)
English: Abnormal heart rhythms (arrhythmias):
Maltese: Ritmi tal-qalb mhux normali (arritmiji):
English: • medicines to treat depression - such as nefazodone, tricyclic antidepressants
Maltese: • mediċini biex jikkuraw id-depressjoni - bħal nefazodone, antidepressanti triċikliċi
English: Invirase 500 mg film-coated tablets Saquinavir
Maltese: Invirase 500 mg pilloli miksija b'rita Saquinavir
English: The effect of treatment initiation with a dosing regimen of Invirase/ritonavir 500 /100 mg twice daily in combination with 2 NRTIs for the first 7 days of treatment followed by Invirase/ritonavir 1000 / 100 mg twice daily in combination with 2 NRTIs in the subsequent 7 days on QTc interval, PK, and viral load was evaluated in an open-label 2-week observational study in 23 HIV-1 infected, treatmentnaïve patients initiating Invirase/ritonavir therapy.
Maltese: L-effett ta' bidu ta' kura b'kors ta' dożaġġ ta' Invirase/ritonavir 500 /100 mg darbtejn kuljum flimkien ma' 2 NRTIs għall-ewwel 7 ijiem ta' kura segwit minn Invirase/ritonavir 1000 /100 mg darbtejn kuljum flimkien ma' 2 NRTIs fis-7 ijiem ta' wara fuq l-interval QTc, PK, u l-viral load kien evalwat fi studju ta' osservazzjoni open-label ta' ġimagħtejn fi 23 pazjent infettati b'HIV-1 li qatt ma ħadu kura qabel, li bdew terapija b'Invirase/ritonavir.
English: Invirase 500 mg film-coated tablets are light orange to greyish or brownish orange tablets of oval shape with the marking "SQV 500" on one side and "ROCHE" on the other side.
Maltese: Invirase 500 mg, pilloli miksija b'rita huma pilloli oranġju ċar għal oranġju fil-gris jew fil-kannella, ta' forma ovali, b'marka “SQV 500” fuq naħa waħda u ‘ROCHE' fuq in-naħa l-oħra.
English: • certain strong pain killers (narcotics) - such as alfentanyl, fentanyl, methadone
Maltese: • ċertu mediċini qawwija li jtaffu l-uġigħ (narkotiċi) - bħal alfentanyl, fentanyl, methadone
English: Hypersensitivity
Maltese: Sensittività eċċesiva
English: Invirase/ritonavir is contraindicated in patients with decompensated hepatic impairment (see sections 4.3 and 4.4).
Maltese: Invirase/ritanovir huwa kontra-indikat f'pazjenti b'indeboliment dekompensat tal-fwied (ara sezzjonijiet 4.3 u 4.4).
English: • Take one 100 mg capsule of ritonavir (Norvir) twice a day.
Maltese: • Ħu kapsula waħda ta' ritonavir(Norvir) 100 mg darbtejn kuljum.
English: The G48V mutation, previously identified in vitro as a saquinavir signature mutation, was present at baseline in virus from three patients, none of whom responded to therapy.
Maltese: Il-mutazzjoni G48V, identifikat qabel in vitro bħala mutazzjoni karatteristika ta' saquinavir, kienet preżenti fil-linja bażi fil-virus minn tliet pazjenti, li l-ebda wieħed minnhom ma rrisponda għat-terapija.
English: Fosamprenavir 700 mg bid (saquinavir/ritonavir 1000/100 mg bid)
Maltese: 700 mg bid (saquinavir/ritonavir 1000/100 mg bid)
English: (90% CI 98%-167%) Rifabutin AUC0-72 ↑ 53% (90% CI 36%-73%) Rifabutin Cmax ↑ 86% (90% CI 57%-119%)
Maltese: Parti attiva ta' rifabutin* AUC0-72 ↑ 134 % (90 % CI 109 %-162 %) Parti attiva ta' rifabutin* Cmax ↑ 130 % (90 % CI 98 %-167 %) Rifabutin AUC0-72 ↑ 53 % (90 % CI 36 %-73 %) Rifabutin Cmax ↑ 86 % (90 % CI 57 %-119 %)
English: Similarly, saquinavir might also modify the pharmacokinetics of other medicinal products that are substrates for CYP3A4 or P-gp.
Maltese: B'mod simili, saquinavir jista' wkoll jimmodifika il-farmakokinetika ta' prodotti mediċinali oħra li huma sottostrati ta' CYP3A4 jew P-gp.
English: Ritonavir AUC ↑ 41%
Maltese: - Saquinavir AUC ↑ 13 %
English: Steady state saquinavir exposures observed in paediatric trials were substantially higher than historical data in adults where dose- and exposure-dependent QTc and PR prolongation were observed (see section 4.4).
Maltese: Esponimenti għal saquinavir fi stat fiss osservati fi provi pedjatriċi kienu sostanzjalment ogħla minn dejta storika fl-adulti fejn kienu osservati titwil ta' QTc u PR dipendenti mid-doża u l-esponiment (ara sezzjoni 4.4).
English: • hypersensitivity to the active substance or to any of the excipients listed in section 6.1
Maltese: • sensittività eċċessiva għas-sustanza attiva jew għal kwalunkwe sustanza mhux attiva elenkata fis-sezzjoni 6.1
English: Resistance
Maltese: Atorvastatin
English: This is due to induction of drug metabolising enzymes and/or transport proteins by St. John's wort.
Maltese: Dan jiġri minħabba l-induzzjoni ta' enżimi metabolizzanti tal-mediċina u/jew proteini tat-trasport minn St.
English: Patients with haemophilia: There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in haemophiliac patients type A and B treated with protease inhibitors.
Maltese: Kien hemm rapporti ta' żjieda fil-fsada (ħruġ ta' demm), inkluż ematomi u emartrożi spontanji tal-ġilda, f'pazjenti b'emofilja tat-tip A u B ikkurati bl-inibituri tal-protease.
English: Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis carinii pneumonia.
Maltese: Eżempji rilevanti huma retinite minn cytomegalovirus, infezzjonijiet ġeneralizzati u/jew lokalizzati minn mikobakterja, u pnewmonja ikkawżata minn Pneumocystis carinii.
English: Day 14 mg (n=21)
Maltese: Jum 14 mg (n=21)
English: Other reported side effects (in more than one in a hundred but less than one in ten persons), which may occur are: rash, itching, eczema and dry skin, hair loss, dry mouth, headache, peripheral neuropathy (a disturbance of the nerves in the feet and hands that may take the form of numbness, pins and needles, shooting or burning pain), weakness, dizziness, libido problems, taste alteration, mouth ulcers, dry lips, abdominal discomfort, indigestion, weight loss,constipation, increased appetite, muscle spasms and shortness of breath.
Maltese: Effetti sekondarji oħra irrappurtati (f'aktar minn wieħed kull mija iżda f'inqas minn wieħed f'kull għaxar persuni) li jistgħu jseħħu huma: raxx, ħakk, ekżema u ġilda xotta, jaqgħa x-xahar, ħalq xott, uġigħ ta' ras, newropatija periferali (disturbi tan-nervaturi fis-saqajn u fl-idejn li jistgħu jieħdu forma ta' tnemnim, tingis bħal labar, uġigħ qisu ħruq jew li jiġri mal-ġisem), dgħjufija, sturdament, problemi ta' libido, tibdil fit-togħma, ulċeri fil-ħalq, xufftejn xotti, skomdu addominali, indiġestjoni, telf ta' piż, stitikezza, żjieda fl-aptit, spażmi tal-muskoli, u qtugħ ta' nifs.
English: Mutagenesis: Mutagenicity and genotoxicity studies, with and without metabolic activation where appropriate, have shown that saquinavir has no mutagenic activity in vitro in either bacterial (Ames test) or mammalian cells (Chinese hamster lung V79/HPRT test).
Maltese: Studji ta' mutaġeniċità u ġenotossiċità, bi jew bla attivazzjoni metabolika fejn xieraq, urew li saquinavir m'għandu l-ebda attività mutaġenika in vitro f'ċelluli tal-batterja (test ta' Ames) jew tal-mammali (test V79/HPRT tal-pulmun tal-ħamster Ċiniż).
English: Ritonavir can affect the pharmacokinetics of other medicinal products because it is a potent inhibitor of CYP3A4 and P-gp.
Maltese: Ritonavir jista' jaffettwa l-farmakokinetika ta' prodotti mediċinali oħra minħabba li huwa inibitur qawwi ta' CYP3A4 u P-gp.
English: In HIV-infected patients, Invirase or saquinavir soft capsules in combination with ritonavir at doses of 1000/100 mg twice daily provide a systemic exposure of saquinavir over a 24 hour period similar to or greater than that achieved with saquinavir soft capsules 1200 mg three times daily (see section 5.2).
Maltese: F'pazjenti infettati b'HIV, Invirase jew kapsuli rotob ta' saquinavir flimkien ma' ritonavir f'dożi ta' 1000/100 mg darbtejn kuljum jipprovdu esponiment sistemiku ta' saquinavir tul perijodu ta' 24 siegħa simili jew aktar minn dak li ntlaħaq b'kapsuli rotob ta' saquinavir 1200 mg tliet darbiet kuljum (ara sezzjoni 5.2).
English: Antifungals Ketoconazole 200 mg qd (saquinavir/ritonavir 1000/100 mg bid)
Maltese: Ketoconazole 200 mg qd (saquinavir/ritonavir 1000/100 mg bid)
English: Treatment of overdose with saquinavir should consist of general supportive measures, including monitoring of vital signs and ECG, and observations of the patient's clinical status.
Maltese: Kura ta' doża eċċessiva b'saquinavir għandha tikkonsisti minn miżuri ta' support ġenerali, inkluż sorveljanza tas-sinjali vitali u ECG, u osservazzjonijiet ta' l-istat kliniku tal-pazjent.
English: Day 7 mg (n=21)
Maltese: Jum 7 mg (n=21)
English: Table 9: Mean (CV%) PK Parameters following administration of the Modified Invirase/ritonavir Regimen in Treatment Naïve HIV-1 infected Patients initiating treatment with Invirase/ritonavir Parameter Day 3 500/100 mg (n=22)
Maltese: Tabella 9: Parametri PK medji (CV%) wara l-għoti ta' kors modifikat ta' Invirase/ritonavir lill-Pazjent infettati b'HIV-1 li
English: Fluticasone propionate 50 mcg qid, intranasal (ritonavir 100 mg bid)
Maltese: Fluticasone propionate 50 mcg qid, mill imnieħer
English: Other less frequently reported side effects (in more than one in one thousand persons but less than one in a hundred persons) include: decreased appetite, visual disturbance, inflammation of the liver, fits, allergic reactions, blisters, sleepiness, abnormal renal function, inflammation of the pancreas, yellowing of the skin or whites of the eyes caused by liver problems and Steven's Johnson syndrome (a serious illness with blistering of the skin, eyes, mouth and genitals).
Maltese: Effetti sekondarji oħra, irrappurtati b'mod inqas frekwenti (f'aktar minn wieħed kull elf persuna iżda f'inqas minn wieħed f'kull mitt persuna) jinkludu: tnaqqis fl-aptit, disturbi fil-vista, infjammazzjoni tal-fwied, eċċessjonijiet, reazzjonijiet allerġiċi, infafet, ngħas, funzjoni mhux normali tal-kliewi, infjammazzjoni tal-frixa, il-ġilda jew l-abjad tal-għajnejn jisfaru ikkawżat minn problemi fil-fwied u sindrome ta' Steven Johnson (marda serja b'infafet fil-ġilda, għajnejn, ħalq u ġenitali).
English: Antidepressants Tricyclic antidepressants (e.g. amitriptyline, imipramine, clomipramine) (saquinavir/ritonavir)
Maltese: Anti-depressanti triċikliċi (eż. amitriptyline,
English: The pharmacokinetics, safety and activity of saquinavir have been evaluated in an open label, multicenter study in 18 children aged 4 months to less than 6 years old in which saquinavir (50 mg/kg bid up to the adult dose of 1000 mg bid) was administered in combination with ritonavir oral solution (3 mg/kg bid for body weight from 5 to <15 kg, 2.5 mg/kg bid for body weight from 15 to 40 kg and
Maltese: Il-farmakokinetika, is-sigurtà u l-attività ta' saquinavir kienu evalwati fi studju open label, b'ħafna ċentri fi 18-il tifel/tifla b'età minn 4 xhur sa inqas minn 6 snin fejn saquinavir (50 mg/kg bid sad-doża għall-adulti ta' 1000 mg bid) ingħata flimkien ma' soluzzjoni orali ta' ritonavir (3 mg/kg bid għal piż tal-ġisem minn 5 sa <15 kg, 2.5 mg/kg bid għal piż tal-ġisem minn 15 sa 40 kg u 100 mg bid għal piż tal-ġisem >40 kg) flimkien ma' ≥2 ARVs fl-isfond.
English: Light orange to greyish or brownish orange film-coated tablet of oval cylindrical biconvex shape with the marking "SQV 500" on the one side and "ROCHE" on the other side.
Maltese: Pillola miksija b'rita oranġjo ċar għal griż jew kannella, b'forma ovali ċilindrika u tonda miż-żewġ naħat bil-marki "SQV 500" fuq naħa u "ROCHE" fuq in-naħa l-oħra.
English: Invirase/ritonavir and ergot alkaloids is contra-indicated (see section 4.3).
Maltese: L-użu ta' Invirase/ritonavir flimkien ma' alkalojdi ergot huwa kontraindikat (ara sezzjoni 4.3).
English: In an additional four subjects administered 10.5 mg 14C-saquinavir intravenously, 81 % and 3 % of the intravenously administered radioactivity was recovered in faeces and urine, respectively, within 4 days of dosing.
Maltese: F'erba' soġġetti oħra li ngħataw 10.5 mg ta' 14C-saquinavir ġol-vina 81 % u 3 % tar-radjuattività mogħtija ġol vina kienet irkuprata fl-ippurgar u fl-awrina, rispettivament, sa 4 ijiem mill-għotja tad-doża.
English: In combination with ritonavir
Maltese: Interazzjoni ma' ritonavir:
English: Paraesthesia, peripheral neuropathy, dizziness, dysgeusia, headache
Maltese: Parasteżija, newropatija periferali, sturdament, disġewżja, uġigħ ta' ras
English: Co-administration of Invirase/ritonavir with orally administered midazolam is contraindicated (see section 4.3).
Maltese: L-għoti ta' Invirase/ritonavir flimkien ma' midazolam orali huwa kontraindikat (ara sezzjoni 4.3).
English: Proportion with VL < 50 copies/ml at week 48, On Treatment
Maltese: Proporzjon b'VL < 50 kopji/ml wara 48 ġimgħa, B'Kura
English: There was no QT prolongation > 500 msec and no torsade de pointes in the study (see also section 4.4).
Maltese: Ma kien hemm l-ebda titwil ta' QT ta' > 500 msec u l-ebda torsade de pointes flistudju (ara wkoll sezzjoni 4.4).
English: The CD4 lymphocyte count expressed as percentage mean CD4 increased by a mean of 2.97% over the same 48 week period.
Maltese: L-għadd ta' limfoċiti CD4 (imfisser bħala perċentwali ta' CD4 medja) żdied b'medja ta' 2.97% matul l-istess perijodu ta' 48 ġimgħa.
English: Didanosine 400 mg single dose (saquinavir/ritonavir 1600/100 mg qd)
Maltese: Didanosine doża waħda ta' 400 mg (saquinavir/ritonavir 1600/100 mg qd)
English: Adults over 60 years: The experience with Invirase in adults over 60 years is limited.
Maltese: Adulti b'età 'l fuq minn 60 sena: L-esperjenza b'Invirase f'adulti b'età 'l fuq minn 60 sena hija limitata.
English: Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events.
Maltese: Pazjenti b'epatite kronika B jew C u kkurati b'terapija mħallta antiretrovirali huma f'riskju akbar għall-effetti avversi serji u potenzjalment fatali tal-fwied.
English: Glucocorticoids: Concomitant use of boosted saquinavir and fluticasone or other glucocorticoids that are metabolised by CYP3A4 is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression (see section 4.5).
Maltese: L-użu ta' saquinavir msaħħaħ flimkien ma' fluticasone jew glukokortikojdi oħra li huma metabolizzati minn CYP3A4 mhux rakkomandat sakemm il-benefiċċju potenzjali tal-kura ma jkunx akbar mir-riskju ta' effetti kortikosterojdi sistemiċi, inkluż is-sindromu ta' Cushing u soppressjoni ta' l-adrenali (are sezzjoni 4.5).
English: - For patients with a baseline QT interval < 450 msec, an on-treatment ECG should be performed.
Maltese: - Għall-pazjenti b'intervall QT fil-linja bażi ta' < 450 msec, għandu jitwettaq ECG waqt ilkura.
English: • ergot alkaloids - for migraine attacks
Maltese: • ergot alkaloids għall-attakki ta' emikranja
English: • certain medicines used to treat the symptoms of Benign Prostatic Hyperplasia (an increase in size of the prostate) such as alfuzosin
Maltese: • ċertu mediċini użati biex jittrattaw is-sintomi ta' Iperplasja Benija tal-Prostata (żieda fid-daqs tal prostata) bħal alfuzosin
English: (90 % CI 44-131 %) Saquinavir Cmax ↑ 75% (90 % CI 38-123 %) Ritonavir ↔
Maltese: Saquinavir AUC ↑ 82 % (90 % CI 44-131 %) Saquinavir Cmax ↑ 75 % (90 % CI
English: Metabolism of pravastatin and fluvastatin is not dependent on CYP3A4.
Maltese: Il-metaboliżmu ta' pravastatin u fluvastatin mhux dipendenti fuq CYP3A4.
English: HIV protease inhibitors (PIs) Atazanavir 300 mg qd (saquinavir/ritonavir 1600/100 mg qd)
Maltese: Atazanavir 300 mg qd (saquinavir/ritonavir 1600/100 mg qd)
English: Dose of maraviroc should be decreased to 150 mg bid with monitoring.
Maltese: Iddoża ta' maraviroc għandha titnaqqas għal 150 mg bid b'sorveljanza.
English: - For treatment-naïve patients initiating treatment with Invirase/ritonavir 500/100 mg two times daily for the first 7 days of treatment followed by Invirase 1000 mg two times daily with ritonavir 100 mg two times daily after 7 days and with a baseline QT interval < 450 msec, an on-treatment ECG is suggested after approximately 10 days of therapy.
Maltese: 500/100 mg darbtejn kuljum għall-ewwel 7 ijiem ta' kura segwit minn Invirase 1000 mg darbtejn kuljum b'ritonavir 100 mg darbtejn kuljum wara 7 ijiem u b'intervall QT fil-linja bażi ta' < 450 msec, ECG waqt il-kura hija ssuġġerita wara madwar 10 ijiem ta' terapija.
English: There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in haemophilic patients type A and B treated with protease inhibitors (see section 4.4).
Maltese: Kien hemm rapporti ta' żjieda ta' fsada, inkluż ematomi u ematrożi spontanji fil-ġilda, f'pazjenti blemofilja tat-tip A u B kkurati b'inibituri tal-protease (ara sezzjoni 4.4).
English: Invirase should only be given in combination with ritonavir and other antiretroviral medicinal products (see section 4.2).
Maltese: Invirase għandu jingħata biss flimkien ma' ritonavir u prodotti mediċinali antiretrovirali oħrajn (ara sezzjoni 4.2).
English: Itraconazole is a moderately potent inhibitor of CYP3A4.
Maltese: Itraconazole huwa inibitur qawwi b'mod moderat ta' CYP3A4.
English: The presence of 3 or more mutations was associated with reduced response to saquinavir/ritonavir.
Maltese: Ilpreżenza ta' 3 mutazzjonijiet jew aktar kienet assoċjata ma' rispons imnaqqas għal saquinavir/ritonavir.
English: Immune Reactivation Syndrome: In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Maltese: Sindromu tar-Rijattivazzjoni Mmuni: f'pazjenti nfettati b'HIV b'defiċjenza qawwija fl-immunità fiżżmien li nbdiet it-terapija antiretrovirali kombinata (CART), reazzjoni nfjammatorja għall-patoġeni opportunistiċi astintomatiċi jew residwi tista' sseħħ u tikkawża kondizzjonijiet kliniċi serji, jew taggrava s-sintomi.
English: • certain medicines (so called tyrosine kinase inhibitors) used to treat different types of cancer such as dasatinib and sunitinib.
Maltese: • ċertu mediċini (l-hekk imsejħa inibituri ta' tyrosine kinase) użati biex jittrattaw tipi differenti ta'
English: Median Baseline HIV-1 RNA, log10 copies/ml (IQR) Median Baseline CD4+ Cell Count, cells/mm3 (IQR) † data from clinical study report
Maltese: Bla esperjenza ta' PI (%) Linja bażi Medjana HIV-1 RNA, log10 kopji/ml (IQR)
English: • recently taken the HIV medicine rilpivirine.
Maltese: • riċentement ħadt il-mediċina rilpivirine għall-HIV.
English: Saquinavir selectively inhibits the HIV protease, thereby preventing the creation of mature infectious virus particles.
Maltese: Saquinavir jinibixxi b'mod selettiv il-protease tal-HIV u b'hekk jipprevjeni il-formazzjoni ta' partiċelli nfettivi tal-virus maturi.
English: Benzodiazepines Midazolam 7.5 mg single dose (oral) (saquinavir/ritonavir 1000/100 mg bid)
Maltese: Midazolam 7.5 mg doża waħda (orali) (saquinavir/ritonavir 1000/100 mg bid)
English: Dose-dependent prolongations of QT and PR intervals have been observed in healthy volunteers receiving ritonavir-boosted Invirase (see section 5.1).
Maltese: F'voluntiera b'saħħithom li jirċievu Invirase imsaħħaħ b'ritonavir kien osservat titwil tal-intervalli QT u PR dipendenti mid-doża (ara sezzjoni 5.1).
English: (unboosted saquinavir)
Maltese: (saquinavir/
English: On Day 3, the upper 1-sided 95% confidence interval of the maximum mean difference in pre-dose baseline-corrected QTcS (study specific heart rate corrected QT) between the active drug and placebo arms was > 10 msec for the two ritonavir-boosted Invirase treatment groups (see results in Table 3).
Maltese: F'Ġurnata 3, l-ogħla intervall ta' kunfidenza ta' 95% fuq naħa waħda tad-differenza massima medja f'QTcS ta' qabel id-doża kkoreġut għal-linja bażi (QT ikkoreġut għar-rata tal-qalb speċifiku għall-istudju) bejn il-gruppi ta' mediċina attiva u dawk tal-plaċebo kienet > 10 msec għaż-żewġ gruppi ta' kura ta' Invirase imsaħħaħ b'ritonavir (ara r-riżultati f'Tabella 3).
English: In the MaxCmin1 study, the safety and efficacy of saquinavir soft capsules/ritonavir 1000/100 mg twice daily plus 2 NRTIs/Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) was compared to indinavir/ritonavir 800/100 mg twice daily plus 2 NRTIs/NNRTIs in over 300 (both protease inhibitor treatment naïve and experienced) subjects.
Maltese: Fl-istudju MaxCmin1, is-sikurtà u l-effikaċja ta' kapsoli rotob ta' saquinavir/ritonavir 1000/100 mg darbtejn kuljum ma' 2 NRTIs/Inibituri tar- Reverse Transcriptase Non-Nucleoside (NNRTIs) kienu mqabbla ma' indinavir/ritonavir 800/100 mg darbtejn kuljum ma' 2 NRTIs/NNRTIs f'aktar minn 300 (kemm b'esperjenza ta' kura b'inibituri tal-protease kif ukoll bla esperjenza) soġġett.
English: Antimycobacterials Rifampicin 600 mg qd (saquinavir/ritonavir 1000/100 mg bid)
Maltese: Rifampicin 600 mg qd (saquinavir/ritonavir 1000/100 mg bid)
English: Effects of high fluticasone systemic exposure on ritonavir plasma levels yet unknown.
Maltese: L-effetti ta' esponiment sistemiku għoli ta' fluticasone fuq il-livelli fil-plażma ta' ritonavir għadhom mhux magħrufa.
English: Saquinavir inhibited both hERG current and L-type Ca++ channel current with respective IC50s of 4.7 and 6.3 μM.
Maltese: Fi studji elettrofiżjoloġiċi, saquinavir impedixxa l-kurrent tal-hERG b'IC50 ta' 4.7 μM u impedixxa il-kurrent tal-kanali tal-Ca tat-tip L b'IC50 ta' 6.3 μM.